State Of Wyoming Amicus Therapeutics, Inc. Transaction History

State Of Wyoming

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$11.43 - $14.24 $36,495 - $45,468	3,193 New	3,193 $37,000
Q2 2023 Aug 14, 2023	BUY	$10.72 - $13.3 $90,090 - $111,773	8,404 Added 180.93%	13,049 $163,000
Q1 2023 May 12, 2023	SELL	$10.91 - $13.54 $126,665 - $157,199	-11,610 Reduced 71.42%	4,645 $51,000
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $160,761 - $206,438	16,255 New	16,255 $198,000
Q2 2022 Aug 15, 2022	SELL	$6.23 - $11.12 $240,527 - $429,320	-38,608 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$7.89 - $12.48 $12,797 - $20,242	1,622 Added 4.39%	38,608 $365,000
Q4 2021 Feb 11, 2022	BUY	$9.82 - $12.44 $58,851 - $74,552	5,993 Added 19.34%	36,986 $427,000
Q3 2021 Feb 11, 2022	SELL	$8.74 - $11.84 $14,709 - $19,926	-1,683 Reduced 5.15%	30,993 $296,000
Q2 2021 Feb 11, 2022	BUY	$8.71 - $10.72 $258,782 - $318,501	29,711 Added 1002.06%	32,676 $315,000
Q1 2021 Feb 08, 2022	BUY	$9.2 - $23.86 $27,277 - $70,744	2,965 New	2,965 $29,000

278

324M

260K

261K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $3B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.